1. Home
  2. SAGE vs ABUS Comparison

SAGE vs ABUS Comparison

Compare SAGE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • ABUS
  • Stock Information
  • Founded
  • SAGE 2010
  • ABUS 2005
  • Country
  • SAGE United States
  • ABUS United States
  • Employees
  • SAGE N/A
  • ABUS N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SAGE Health Care
  • ABUS Health Care
  • Exchange
  • SAGE Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • SAGE 571.1M
  • ABUS 611.0M
  • IPO Year
  • SAGE 2014
  • ABUS N/A
  • Fundamental
  • Price
  • SAGE $9.12
  • ABUS $3.12
  • Analyst Decision
  • SAGE Hold
  • ABUS Strong Buy
  • Analyst Count
  • SAGE 18
  • ABUS 4
  • Target Price
  • SAGE $9.89
  • ABUS $5.50
  • AVG Volume (30 Days)
  • SAGE 1.8M
  • ABUS 924.5K
  • Earning Date
  • SAGE 07-30-2025
  • ABUS 07-31-2025
  • Dividend Yield
  • SAGE N/A
  • ABUS N/A
  • EPS Growth
  • SAGE N/A
  • ABUS N/A
  • EPS
  • SAGE N/A
  • ABUS N/A
  • Revenue
  • SAGE $47,404,000.00
  • ABUS $6,403,000.00
  • Revenue This Year
  • SAGE $101.71
  • ABUS $3.35
  • Revenue Next Year
  • SAGE $42.30
  • ABUS N/A
  • P/E Ratio
  • SAGE N/A
  • ABUS N/A
  • Revenue Growth
  • SAGE N/A
  • ABUS N/A
  • 52 Week Low
  • SAGE $4.62
  • ABUS $2.71
  • 52 Week High
  • SAGE $13.47
  • ABUS $4.73
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 66.62
  • ABUS 45.09
  • Support Level
  • SAGE $9.10
  • ABUS $3.10
  • Resistance Level
  • SAGE $9.36
  • ABUS $3.20
  • Average True Range (ATR)
  • SAGE 0.10
  • ABUS 0.11
  • MACD
  • SAGE -0.09
  • ABUS -0.01
  • Stochastic Oscillator
  • SAGE 29.69
  • ABUS 42.19

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: